Actos side effects

What side effects can Pioglitazone have?

Below you will find the most important information about possible known side effects of pioglitazone.
These side effects do not occur, but you can. Because every person reacts differently to medication. Please also note that the type and frequency of side effects may vary depending on the drug formulation (eg tablet, syringe, ointment).

Common side effects:
Anemia, blurred vision, weight gain, joint pain, headache, erectile dysfunction, blood in the urine.

Uncommon Side Effects:

Side effects without frequency:
accumulations of water in the retina at the point of sharpest vision (macular edema).

In combination with other blood sugar depressants from the drug group of sulfonylureas, the following side effects occur:
Common side effects:
bloating, weight gain, dizziness.

Uncommon side effects:
Dizziness, blurred vision, fatigue, increased blood lactate dehydrogenase levels, increased appetite, low blood sugar, headache, sugar in urine, protein in urine, sweating.

In a triple combination with metformin and sulfonylureas, the following side effects occur:
Very common side effects:

Common side effects:
joint pain, weight gain, blood creatinine phosphokinase increase.

In combination with insulin the following side effects occur:
Very common side effects:
Water retention in tissue,

Common side effects:
Hypo, bronchitis, weight gain, back pain, joint pain, shortness of breath, heart failure.

Special features:
Since the introduction of the drug into the market, several cases of biliary and hepatic dysfunction as well as one case of acute fatal liver failure have occurred. It is therefore recommended, especially during the first months of therapy, to have the blood glucose levels checked every four weeks.

Pioglitazone appears to increase bone fracture risk in women. In studies comparing oral antidiabetics, fractures were significantly more frequent (2.7 percent) among participating women taking pioglitazone than other sugar medications (1.5 percent). Men were not affected by this side effect. Fractures predominantly involved the upper arm, hand or foot, while broken bones at the typical sites of osteoporosis (hip, spine) were no more common with pioglitazone than in the control groups. The risk of fractures is higher the longer patients are treated with pioglitazone.

Patients with benign ulcers on the ovaries (polycystic ovary syndrome) often suffer from a lack of ovulation and are therefore only partially fertile. Due to the improved insulin action, the treatment with pioglitazone can lead to the re-establishment of ovulation and thus the possibility of pregnancy. If a patient wishes to be pregnant or if she is pregnant, the treatment should be discontinued.

In a study on influencing the blood vessel state by pioglitazone (prospective pioglitazone clinical trial in macrovascular events), the drug appears to lower the risk of heart attack but increases the risk of developing or worsening cardiac insufficiency increase. For cardiac patients, this study should be included in the benefit-risk assessment by the physician.

Patients who experience weight gain, tissue retention, urinary blood, urinary changes or urinary frequency should inform their doctor.

Recent studies have indicated that particularly long-term treatment with the drug (after two years) increases the risk of bladder cancer by nearly 40%. Since April 2011, drugs with the drug are therefore no longer at the expense of the statutory health insurance companies prescription.

What interactions does pioglitazone show?

Please note that the interactions may vary depending on the drug formulation of a drug (eg tablet, syringe, ointment).

Non-steroidal anti-inflammatory drugs (group of anti-pain and anti-inflammatory drugs) may increase the risk of tissue fluid retention (edema) when co-administered with pioglitazone.

The concomitant use of pioglitazone with the blood fat countermeasure gemfibrozil leads to an increase in the concentration of pioglitazone in the blood three-fold. Because of the potential increased risk of dose-related side effects, a reduction in pioglitazone dosage may be required by the physician if gemfibrozil is co-administered. Frequent glycemic control is necessary.

Concomitant use of pioglitazone with the tuberculosis drug rifampicin reduced the blood concentration of pioglitazone by more than half. The doctor will therefore increase the Pioglitazondosierung when given with rifampicin and also recommend a frequent blood sugar control.

Potential Actos side effects may include: